Ozempic Cuts Depression and Anxiety Risk by Up to 44% in Landmark Study
A study of 100,000 people found semaglutide users had 44% lower depression risk and 42% fewer psychiatric hospitalizations.
20 articles
A study of 100,000 people found semaglutide users had 44% lower depression risk and 42% fewer psychiatric hospitalizations.
New research reveals GLP-1 drugs like Ozempic significantly reduce depression, anxiety, and substance use disorders alongside weight management.
Clinical trial shows solriamfetol significantly improves alertness and performance in workers who start before sunrise.
A Rutgers study finds GLP-1 users show dramatically weaker links between impulsivity, alcohol use, and violent behavior.
New NIH research reveals the brain-cell signaling mechanism behind GLP-1 drug plateaus and a potential way to extend their effects.
A home-based walking and resistance program improved attention and reduced observable cognitive decline in chemotherapy patients over 6 weeks.
A 12-week clinical trial found older adults taking probiotics with antidepressants had greater reductions in depression and anxiety than placebo.
A small trial found tocilizumab, an anti-inflammatory drug, cut depression remission rates better than SSRIs by targeting IL-6, not brain chemistry.
Blocking the protein PTP1B boosted memory and cleared brain plaque in mice, with potential links to diabetes and obesity treatment.
A Cochrane review of 20,000+ patients finds amyloid-clearing drugs offer no meaningful benefit and raise brain bleed and swelling risks.
A new tool that boosts mitochondrial activity in neurons restored memory in dementia mice, suggesting energy failure drives Alzheimer's symptoms.
New gene therapy zorevunersen dramatically reduced seizures in children with severe Dravet syndrome epilepsy while improving quality of life.
Scientists used advanced brain imaging to reveal how ketamine reshapes key receptors in specific brain regions to quickly lift severe depression.
UK study of 165,000 dementia patients finds risperidone increases stroke risk across all groups, challenging safety assumptions.
New mouse research finds the trendy D+Q senolytic combo severely damages myelin, raising red flags for longevity self-experimenters.
UK study of 165,000 dementia patients finds risperidone increases stroke risk across all groups, challenging safety assumptions.
Major study identifies three existing drugs that could be repurposed to fight Alzheimer's disease, offering faster path to treatment.
New p-tau217 blood test forecasts Alzheimer's symptoms within 3-4 years, potentially revolutionizing early intervention strategies.
New research identifies FTL1 protein as key driver of brain aging. Reducing it restored memory and neural connections in mice.
Speed-of-processing training in adults 65+ showed lasting protection against dementia in groundbreaking 20-year study.